IRIS
TORTORA, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.866
AS - Asia 3.687
EU - Europa 2.651
SA - Sud America 434
AF - Africa 104
Continente sconosciuto - Info sul continente non disponibili 80
OC - Oceania 1
Totale 10.823
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.693
SG - Singapore 1.718
RU - Federazione Russa 1.203
VN - Vietnam 691
CN - Cina 673
UA - Ucraina 379
BR - Brasile 346
HK - Hong Kong 293
DE - Germania 217
IT - Italia 190
FR - Francia 145
FI - Finlandia 131
CA - Canada 102
NL - Olanda 96
GB - Regno Unito 82
SE - Svezia 71
IE - Irlanda 65
IN - India 47
BD - Bangladesh 46
JP - Giappone 40
AR - Argentina 32
CI - Costa d'Avorio 32
MX - Messico 29
PL - Polonia 25
ZA - Sudafrica 23
PH - Filippine 22
KR - Corea 20
PK - Pakistan 19
IQ - Iraq 17
EC - Ecuador 16
MA - Marocco 14
TW - Taiwan 14
ID - Indonesia 13
TH - Thailandia 12
VE - Venezuela 12
CO - Colombia 11
CR - Costa Rica 9
ES - Italia 9
JM - Giamaica 8
PY - Paraguay 8
TN - Tunisia 8
UZ - Uzbekistan 8
TT - Trinidad e Tobago 7
AT - Austria 6
DZ - Algeria 6
EG - Egitto 6
AE - Emirati Arabi Uniti 5
BE - Belgio 5
CL - Cile 5
JO - Giordania 5
LB - Libano 5
NI - Nicaragua 5
NP - Nepal 5
IL - Israele 4
KH - Cambogia 4
MY - Malesia 4
SA - Arabia Saudita 4
LT - Lituania 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
TR - Turchia 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
CD - Congo 2
CG - Congo 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
EU - Europa 2
HN - Honduras 2
MD - Moldavia 2
PR - Porto Rico 2
RO - Romania 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
ZW - Zimbabwe 2
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
BW - Botswana 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GH - Ghana 1
GI - Gibilterra 1
GR - Grecia 1
IR - Iran 1
KW - Kuwait 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
LY - Libia 1
MQ - Martinica 1
MR - Mauritania 1
Totale 10.734
Salva come PNG Salva come JPEG
Città #
Singapore 776
San Jose 547
Jacksonville 367
Moscow 325
Chandler 301
Hong Kong 278
Beijing 262
Ashburn 246
Ho Chi Minh City 202
Hanoi 151
Millbury 133
Santa Clara 122
Council Bluffs 103
Los Angeles 92
Woodbridge 89
Lauterbourg 86
Amsterdam 84
Princeton 84
The Dalles 82
Munich 64
Buffalo 62
Wilmington 60
Nanjing 56
Ottawa 53
New York 45
Boston 40
Chicago 39
São Paulo 38
Haiphong 32
Ann Arbor 31
Dallas 31
Tokyo 31
Boardman 28
Da Nang 28
Houston 28
Naples 27
Nanchang 25
Hefei 24
Turku 19
Norwalk 18
Phoenix 17
Warsaw 17
Montreal 16
Orem 16
Rio de Janeiro 16
Shenyang 15
Stockholm 15
Atlanta 14
Biên Hòa 13
Kronberg 13
Brooklyn 12
Denver 12
Hebei 12
Helsinki 12
London 12
Mexico City 12
San Francisco 12
Changsha 11
Frankfurt am Main 11
Redondo Beach 11
Rome 11
Tianjin 11
Can Tho 10
Casablanca 10
Islamabad 10
Johannesburg 10
Chennai 9
Poplar 9
Seattle 9
Guangzhou 8
Hải Dương 8
Tashkent 8
Baghdad 7
Belo Horizonte 7
Bắc Ninh 7
Porto Alegre 7
Thái Bình 7
Brasília 6
Bắc Giang 6
Dhaka 6
Jiaxing 6
Kunming 6
Memphis 6
Quận Bình Thạnh 6
Amman 5
Bangkok 5
Charlotte 5
Dublin 5
Falkenstein 5
Guarulhos 5
Managua 5
Manchester 5
Manila 5
Milan 5
Ninh Bình 5
Nuremberg 5
Quận Ba 5
San José 5
Toronto 5
Uberlândia 5
Totale 5.648
Salva come PNG Salva come JPEG
Nome #
Manuale di Oncologia Clinica 237
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 162
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making 159
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. 155
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 144
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 144
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 141
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. 141
A novel thyroid transcript negatively regulated by TSH. 141
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 140
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 136
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 133
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 133
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 132
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 129
Phase I clinical trial of high dose recombinant interleukin-2/veparimil combination in advancer cancer. 129
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 128
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. 126
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 125
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. 123
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 122
EGFR antagonists in cancer treatment. 122
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 122
The mechanisms of resistance to EGFR inhibitors. 120
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 119
Angiogenesis: A target for cancer therapy. 117
Combination of biological therapies in non-small cell lung cancer. 117
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. 117
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 116
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. 115
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 115
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 114
Anti-epidermal growth factor receptor drugs in cancer therapy. 114
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. 114
MONOCLONAL ANTIBODIES TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR. 113
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 112
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 (‘Iressa’) 112
A novel mdm2 antisense oligonucleotide has antitumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. 111
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumour activity with EGFR inhibitors 111
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. 108
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. 108
Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity 108
Altri tumori gastrointestinali 108
Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector. 107
Key cancer cell signal transduction pathways as therapeutic targets. 105
Overexpression of wild-type p53 ovverrides the mitogenic effect of the RIa subunit of protein kinase A in human breast cells. 105
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. 103
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis and cooperates with cytotoxic drugs in human cancer cell lines. 103
Strategies for multiple signalling inhibition. 103
Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. 103
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. 102
INTRINSIC AND ACQUIRED RESISTANCE TO EGFR INHIBITORS IN HUMAN CANCER THERAPY. 102
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 100
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 99
CHEMOSENSITIZATION BY ANTISENSE OLIGONUCLEOTIDES TARGETING MDM2. 99
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 99
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. 96
ZD1839 (‘Iressa’), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. 96
Inhibition of bcl-2 as cancer therapy. 96
Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors. 96
Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease 96
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. 95
8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by ballon injury in vivo. 95
Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. 95
ZD1839 (Iressa): preclinical studies and pharmacology. 95
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. 95
EGFR-targeting agents in oncology 93
Differential sensitivity to non-MHC-restricted rIL-2 activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or PKA subunits. 92
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. 91
ANTITUMOR ACTIVITY OF ZD6474, A VEGFR-2 AND EGFR SMALL MOLECULE TYROSINE KINASE INHIBITOR, IN COMBINATION WITH SC-236, A CYCLOOXYGENASE-2 INHIBITOR. 91
Combined targeting of EGFR and VEGF-dependent pathways: rationale, preclinical studies and clinical applications 91
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 90
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. 90
Effect of thymic extract "thymostimulin" on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. 89
8-Chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in human colon cancer cells 88
ANTITUMOR ACTIVITY OF THE COMBINATION OF CETUXIMAB, AN ANTI-EGFR BLOCKING MONOCLONAL ANTIBODY AND ZD6474, AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES. 86
Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production. 86
Targeting of Epidermal Growth Factor Receptor and Protein Kinase A : Molecular basis and therapeutic applications. 85
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A. 84
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. 83
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting Protein Kinase A in combination with docetaxel and anti-EGFR-Receptor antibody on human breast cancer cell growth. 83
The cAMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 83
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. 81
The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene. 1997 Feb 27;14(8):923-8. 81
Effects of mutant p53 genes on transformation of human mammary epithelial cells. 80
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. 80
Phase I clinical study with 8-Chloro-cAMP and evaluation of immunological effects in cancer patients. 78
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6. 77
Differential effects of type I and type II protein kinase A isoforms on chinese hamster ovary cell cycle and proliferation. 75
Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-indepedence in human prostate cancer 74
Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonuclotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. 73
Inhibition of Cripto expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. 72
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumors sensitive and resistant to anti-EGFR drugs 71
Differential immunohistochemical detection of transforming growth factor , amphiregulin and CRIPTO in human normal and malignant breast tissues. 71
Mechanisms of resistance to HER/erbB inhibitors 71
Helicobacter pylori VacA toxin up-regulates Vascular endothelial growth factor expression in MKN 28 gastric cells through an Epidermal growth factor receptor-, Cyclooxygenase-2-dependent mechanism 68
LY2109761, a Novel Transforming Growth Factor ß Receptor type I and II dual inhibitor, as a Therapeutic Approach to Suppressing Pancreatic Cancer Metastasis. 68
In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. 68
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. 63
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. 59
Totale 10.493
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.423
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.423
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022502 0 0 2 8 9 9 8 18 68 30 138 212
2022/2023656 95 80 21 40 72 73 6 48 90 84 36 11
2023/2024412 16 64 32 67 19 23 16 55 10 6 79 25
2024/20252.556 140 172 7 9 85 68 290 140 172 258 963 252
2025/20264.800 592 366 458 413 857 202 482 263 636 328 93 110
2026/2027321 89 167 65 0 0 0 0 0 0 0 0 0
Totale 10.823